Any page claiming to name the best Semax source without first showing its scoring is asking you to take a verdict on trust, in a market whose entire problem is that trust cannot be checked. So the weights go first, the categories get scored against them, and the ranking falls out at the end.
Key takeaways
- Testing scope carries 40% of the score here, more than price, dispatch and presentation combined, because FDA's stated concern with this compound is a testing question.
- We score supplier categories rather than brand names. Brands change hands and change laboratories, and a category tells you what you can expect to be able to verify.
- Batch traceability is the second weight at 20%. A certificate that does not name a lot cannot be evidence about the vial you are sent.
- Price carries 10%. At $30.00 with the code, or $3.00 per milligram, price is not the variable separating these options and treating it as one is how buyers get sorted into the worst category.
- Our own pick drops marks in two places, and both are stated below rather than left out of the scoring.
The category that wins is represented by the listing below, so the scoring further down can be checked against a live page rather than taken on description.
The vendor we point lifters to
Semax from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
The published certificate for batch 30-05260628 carries a kinetic chromogenic LAL endotoxin test to USP Chapter 85, reporting under 0.20 EU/mL against a 0.5 EU/mL limit, plus a sterility screen. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 21, 2026.
Best Semax source: the weights, published before the result
| Criterion | Weight | What full marks look like |
|---|---|---|
| Testing scope | 40% | Purity against a written specification, identity by mass spectrometry, a bacterial endotoxin figure with a limit, and a microbial screen |
| Batch traceability | 20% | A lot number on the listing, repeated on the document, with a report number that can be checked against the laboratory |
| Domestic stock and dispatch | 15% | US warehouse, stated cut-off, tracked service, no customs stage |
| Price transparency | 10% | A total quantity in milligrams so a per-milligram figure can be calculated at all |
| Compliance behaviour | 10% | Research-use labelling, no human-use claims, no dosing or preparation advice offered |
| Recourse | 5% | A written refund or replacement policy and a contactable business |
Testing scope takes 40% because of what the regulator actually said. FDA writes that compounded drugs containing semax (heptapeptide) "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities", adding that it has no, or limited, safety-related information for proposed routes of administration.
That is a manufacturing and handling objection, not a pharmacological one, and it is answerable by documents. Aggregation and peptide-related impurities come from how material was made, filled and stored. Endotoxin is the measurable residue of the microbial end of that, it does not appear in a purity percentage, and it needs its own assay. So the tests are the part of the regulator's question a buyer can actually check, which is why they outweigh everything else on the sheet.
Price gets 10% deliberately. A vial that lands at $3.00 per milligram is cheap enough that price cannot be the deciding variable, and a scorecard that weighted it higher would rank the worst categories first.
The six categories, scored
| Category | Testing 40 | Traceability 20 | Dispatch 15 | Price 10 | Compliance 10 | Recourse 5 | Total |
|---|---|---|---|---|---|---|---|
| Domestic supplier, combined batch certificate | 36 | 19 | 14 | 9 | 9 | 4 | 91 |
| Domestic supplier, purity-only certificate | 20 | 17 | 13 | 9 | 8 | 4 | 71 |
| Nootropic retailer, nasal spray | 8 | 6 | 12 | 2 | 5 | 4 | 37 |
| Overseas bulk seller | 6 | 5 | 2 | 10 | 3 | 0 | 26 |
| Reseller or group buy | 0 | 0 | 6 | 8 | 1 | 0 | 15 |
| Compounding pharmacy | n/a | n/a | n/a | n/a | n/a | n/a | disqualified |
The interesting gap is not between the top and the bottom, which anyone could guess. It is the twenty-point gap between the first two rows, which are the same kind of business, at similar prices, distinguishable only by what their laboratory report covers.
Why the pharmacy row is disqualified rather than scored
It is worth being exact here, because this is the fact competing pages garble in both directions.
Semax was nominated as a bulk drug substance for use in compounding. It was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was then withdrawn by the nominator. It sits today on FDA's safety risks page under the heading "Bulk drug substances nominated but withdrawn", listed as "Semax (heptapeptide)", and it appears nowhere on FDA's 503A bulk substances page in category 1, 2 or 3.
So "Semax is FDA category 2" is wrong, and "Semax was in category 2" is stale but defensible. Today it is on no category list at all, and there is no FDA approval for it for any indication. The Russian registration covering cognitive and stroke indications is a foreign registration and not something a US pharmacy dispenses against. There is nothing for this category to score on, so it is out of the table rather than at the bottom of it.
Showing the work on the winning row
The category at the top is represented by a listing that publishes two certificates from two laboratories, and the two disagree about how much testing is enough. That disagreement is the evidence.
The Kovera Labs combined report for batch 30-05260628, certified 06/15/2026, covers purity at 99.886% against a stated greater than 98% specification, identity confirmed by LC-MS, net content of 11.23 mg against a 10 mg label, a bacterial endotoxin result below 0.20 EU/mL against a 0.5 EU/mL acceptance limit by kinetic chromogenic LAL to USP Chapter 85 using an E. coli O111:B4 standard across a 0.01 to 1.0 EU/mL detection range, a rapid sterility screen returning no growth and no fungi or yeast detected, and elemental impurities by ICP-MS with lead under 0.5 ppm against a 10 ppm limit, arsenic under 0.15 against 1.5, cadmium under 0.05 against 0.5, and mercury under 0.3 against 3, with spike recoveries between 91% and 102%.
The MZ Biolabs report for lot 30-01260229, analysed 2026-02-09, covers purity at 99.75% by HPLC-UV with the chromatogram and peak list printed, identity by HPLC-MS at 813.35 Da expected against 813.41 Da measured, and quantity at 10.12 mg per vial. It carries no endotoxin result and no sterility screen.
On this scorecard those two documents are twenty points apart, on the same product, from the same store, four months apart. Which is the finding that actually matters: testing scope belongs to a batch, not to a brand, so the question to put to any seller is which lot ships and what its certificate covers. We reached the same conclusion by a different route on the neighbouring Russian heptapeptide in scoring Selank suppliers.
Where our own pick loses marks
A scorecard that gives its preferred answer full marks is a sales page with a table on it. Two deductions, both checkable.
The sterility line is a rapid screen rather than a compendial release. The report describes a two-day incubation at 30 to 35 degrees Celsius and states in its own words that full USP Chapter 71 sterility testing may be required for regulatory compliance. It is more than most certificates in this market carry and it is not the same as a sterility release, which is why testing scores 36 out of 40 rather than 40.
The second deduction is smaller and worth mentioning because noticing it is the skill being taught. The endotoxin page is headed as a kinetic chromogenic LAL assay while the methodology table below lists the assay type as kinetic turbidimetric and a detection wavelength of 660 nm. Both are recognised LAL formats run against the same acceptance limit, so the result stands, but a document that contradicts itself in a detail is one to read rather than skim. Traceability scores 19 rather than 20 for the same reason.
Neither deduction changes the ranking. Both are the sort of thing a page that had scored honestly would find, and a page that had not would omit. The same approach, applied where the failure mode was mitochondrial supplements rather than peptide impurities, is in how we score a MOTS-c supplier.
What the winning row still does not buy
A best-in-category source is a statement about supply. It is not an argument for use.
Semax is a synthetic heptapeptide, seven residues, Met-Glu-His-Phe-Pro-Gly-Pro, the ACTH(4-7) fragment with a proline-glycine-proline tail added to slow enzymatic breakdown, recorded on PubChem as CID 9811102 with the formula C37H51N9O10S and a molecular weight of 813.9. It is marketed at lifters against mental fatigue and flat drive rather than hypertrophy, which is at least honest, since none of its literature concerns muscle.
That literature is thin in the places a Western reader can inspect. A PubMed search for semax returns mostly rodent work and small Russian-language clinical reports, quoted at second hand far more often than they are read, and a clean certificate says nothing about any of it. A complete document closes off one avoidable failure. It is not evidence of an effect.
If a block has gone flat, the honest first checks are duller and better supported, and we work through one of them in protein intake and myostatin.
Frequently asked questions
Why score categories instead of naming vendors?
Because vendors change laboratories, ownership and testing scope, sometimes between batches, while a category tells you what you will be able to verify before you buy. The scoring here is designed to survive a supplier changing its documents next quarter.
Why does testing carry 40% of the score?
Because it is the part of FDA's stated concern a buyer can check. The agency's objection is immunogenicity from aggregation and peptide-related impurities, which is a manufacturing question, and endotoxin plus sterility results are the measurable end of it.
Is the highest purity figure the best source?
No. Purity says the main peak is clean relative to what the detector can see, and says nothing about endotoxin, which is a separate assay, or identity, which needs a mass spectrometry result beside it. A 99.9% figure on a one-page report scores below a 99.4% figure on a four-page one.
Does the best source make Semax safe to use?
No. FDA says it has no, or limited, safety-related information for proposed routes of administration and lacks sufficient information to know whether the drug would cause harm in humans. A laboratory cannot supply human data. Good documentation removes one avoidable problem, not the underlying uncertainty.
How much should a reasonable source cost?
The listing scored here is $59.99 for a 10 mg vial, $30.00 with the code, or $3.00 per milligram. Convert any competing offer to a per-milligram figure before comparing, and treat a large saving as a question about testing scope rather than as a better deal.
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA
- Bulk Drug Substances Used in Compounding Under Section 503A, FDA
- Semax, PubChem CID 9811102
- Certificate of analysis, Semax batch 30-05260628, Kovera Labs
- Certificate of analysis, Semax lot 30-01260229, MZ Biolabs
- Semax literature, PubMed
This article is for educational purposes only and is not medical advice. Semax is not an FDA-approved medicine, has no US prescription route, and material sold by research suppliers is labelled for laboratory use only and not for human consumption. A foreign registration is not an FDA approval or evidence of efficacy by Western regulatory standards. Scores on this page reflect what a buyer can verify from published documents and are not a safety assessment. Speak with a qualified healthcare professional before making any decision involving peptides, injections or unapproved compounds.